A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

High–Temporal/High–Spatial Resolution Breast Magnetic Resonance Imaging Improves Diagnostic Accuracy Compared With Standard Breast Magnetic Resonance Imaging in ...

The FDA's CRL cited the IGNYTE trial's inadequacy and patient heterogeneity as reasons for not supporting RP1's approval. Replimune plans to pursue a Type A meeting to discuss potential accelerated ...

HealthDay News — For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the ...

Erratum: Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue ...

The sBLA is supported by data from the phase 3 CheckMate -76K trial which included 790 patients after complete resection of stage IIB or IIC melanoma. The Food and Drug Administration (FDA) has ...

More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...